David Roth - 31 Mar 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Medical Officer
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
31 Mar 2024
Net transactions value
-$24,975
Form type
4
Filing time
02 Apr 2024, 16:58:50 UTC
Previous filing
14 Dec 2023
Next filing
05 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Options Exercise +2,000 2,000 31 Mar 2024 Direct F1
transaction SYRS Common Stock Options Exercise +13,333 +667% 15,333 31 Mar 2024 Direct F1
transaction SYRS Common Stock Tax liability $24,228 -4,732 -31% $5.12 10,601 01 Apr 2024 Direct F2
transaction SYRS Common Stock Sale $747 -150 -1.4% $4.98 10,451 02 Apr 2024 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Restricted Stock Units Options Exercise $0 -2,000 -33% $0.000000 4,000 31 Mar 2024 Common Stock 2,000 Direct F5, F6
transaction SYRS Restricted Stock Units Options Exercise $0 -13,333 -33% $0.000000 26,667 31 Mar 2024 Common Stock 13,333 Direct F5, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 Represents shares used to cover tax withholding upon the release of restricted stock units.
F3 The sale was effected pursuant to a trading plan adopted on March 27, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F4 The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.97 to $5.02, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F6 Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.
F7 Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024.